



The Drug Utilization Review (DUR) Board Reviewed
the Following New Drugs/Classes on
October 16, 2024

Therapeutic Class	Drug Name	DURB Recommendation*
Muscular Dystrophy Agents		
	<i>Agamree (Oral) Suspension</i>	NP/PA
NASH Agents		
	<i>Rezdiffra (Oral) Tablet</i>	NP/PA
Potassium-Competitive Acid Blockers		
	<i>Voquezna (Oral) Tablet</i>	NP/PA
Topical Ectoparasiticides		
	<i>Xdemvy (Ophthalmic) Solution</i>	NP/PA
NHE3 Inhibitors		
	<i>Xphozah (Oral) Tablet</i>	NP/PA

*All recommendations apply to the PDL unless explicitly stated otherwise; DURB=Drug Utilization Review Board;
P=preferred; NP=non-preferred; PA=prior authorization; PDL=Preferred Drug List; PADL=Providers'
Administered Drug List